The histone reagents are expected to work as tool for researchers seeking to prosecute key drug targets in the field of epigenetics.
The modified histone reagent provision will complement Almac Flexyte FLT assays for epigenetic targets.
Almac array of platform technologies will offer full-length natural histones that possess post-translational modifications at any specified site(s) within the protein.
The reagents will be offered through a catalogue of modified histones and also as a custom synthesis service to meet bespoke customer demands.
Almac Peptide and Protein Technologies vice president Charles Shields said Almac will develop its protein synthesis capability to provide a needed source of tools to the epigenetic research field.
”I am delighted that we are able to offer such capabilities,’ Shields added.